|
Published by: Global Markets Direct
Published: Dec. 26, 2012 - 304 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Herpes Infections Overview
- Therapeutics Development
- An Overview of Pipeline Products for Herpes Infections
- Herpes Infections Therapeutics under Development by Companies
- Herpes Infections Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Herpes Infections Therapeutics – Products under Development by Companies
- Herpes Infections Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Herpes Infections Therapeutics Development
- Vical Incorporated
- GlaxoSmithKline plc
- Antigenics, Inc.
- GenVec, Inc.
- Merck & Co., Inc.
- Piramal Healthcare Limited
- Novartis AG
- Astellas Pharma Inc.
- Alfacell Corporation
- CEL-SCI Corporation
- Intercell AG
- Mymetics Corporation
- NanoViricides, Inc.
- Nutra Pharma Corporation
- Peregrine Pharmaceuticals, Inc.
- CytoGenix, Inc.
- Alnylam Pharmaceuticals, Inc
- Flamel Technologies S.A.
- Starpharma Holdings Limited
- Summit Corporation plc
- BioAlliance Pharma SA
- Clavis Pharma ASA
- Oryzon
- Functional Genetics, Inc.
- Colby Pharmaceutical Company
- Nutri Pharma ASA
- Vironova AB
- Altor BioScience Corporation
- Osel Inc.
- AiCuris GmbH & Co. KG
- Cell Medica Limited
- AlphaVax, Inc.
- Nitric Biotherapeutics, Inc.
- Romark Laboratories, L.C.
- Chimerix, Inc.
- aRigen Pharmaceuticals, Inc.
- Lumavita AG
- Theraclone Sciences, Inc.
- Sinovac Biotech Ltd.
- Wittycell S.A.S.
- Microbiotix, Inc.
- NanoBio Corporation
- PharmaNova Inc.
- Immune Design Inc.
- Redox Pharmaceutical Corporation
- PepTcell Limited
- 4-Antibody AG
- Arisyn Therapeutics Inc.
- Epiphany Biosciences, Inc.
- Cannabis Science, Inc.
- Synergy Pharmaceuticals, Inc.
- Genocea Biosciences, Inc.
- Variation Biotechnologies, Inc.
- AIMM Therapeutics B.V.
- China National Pharmaceutical Group Corporation
- Trellis Bioscience, Inc.
- Vakzine Projekt Management GmbH
- Spider Biotech S.r.l.
- Kala Pharmaceuticals
- Beech Tree Labs, Inc.
- FunZyme BioTechnologies S.A.
- Herpes Infections – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- maribavir - Drug Profile
- FV-100 - Drug Profile
- CyMVectin - Drug Profile
- tenofovir - Drug Profile
- acyclovir - Drug Profile
- TCN-202 - Drug Profile
- RPI-78M - Drug Profile
- RPI-MN - Drug Profile
- famciclovir - Drug Profile
- ASP-0113 - Drug Profile
- simplivir - Drug Profile
- CEL-1000 - Drug Profile
- doxorubicin - Drug Profile
- HSV Vaccine - Drug Profile
- NB-001 - Drug Profile
- LMV-601 - Drug Profile
- Antiviral TCR-Ck - Drug Profile
- Antiviral TCR-Ig - Drug Profile
- 4Ab-028 - Drug Profile
- HSV-2 Vaccine - Drug Profile
- HSV-2 Vaccine - Drug Profile
- AVX-601 - Drug Profile
- ganciclovir - Drug Profile
- ATI-0607 - Drug Profile
- VN-180 - Drug Profile
- HerpV Vaccine - Drug Profile
- AIC-316 - Drug Profile
- valomaciclovir stearate - Drug Profile
- VPM-2001 - Drug Profile
- CMV-Specific T-Cells + Ganciclovir + Valganciclovir + Foscarnet - Drug Profile
- sorafenib tosylate - Drug Profile
- CMV specific cytotoxic T lymphocytes - Drug Profile
- Donor-Derived CMV-pp65 Peptide-Specific T Cells - Drug Profile
- Small Interference Ribonucleic Acids - Drug Profile
- letermovir - Drug Profile
- Cytotoxic T-Lymphocytes - Drug Profile
- valacyclovir hydrochloride - Drug Profile
- SPL-7013 - Drug Profile
- acyclovir CR - Drug Profile
- Zoster - Drug Profile
- valacyclovir hydrochloride - Drug Profile
- RNAi Therapeutic For HSV Infection - Drug Profile
- Liposomal Doxorubicin + Bevacizumab - Drug Profile
- BTL-TML-HSV - Drug Profile
- CMV Glycoprotein B Vaccine - Drug Profile
- CMV gB + MF59 - Drug Profile
- CMV-specific T-cells - Drug Profile
- Human Herpes Virus (HHV) Specific Immune Effector (IE) Cell Therapy - Drug Profile
- cytomegalovirus specific cytotoxic T lymphocytes - Drug Profile
- CMV Specific CTL - Drug Profile
- GSK-1492903-A - Drug Profile
- Cytomegalovirus gB/MF59 Vaccine + MF-59 - Drug Profile
- Cytotect - Drug Profile
- Varicella-zoster vaccine - Drug Profile
- Zoster Vaccine - Drug Profile
- V-212 - Drug Profile
- acyclovir - Drug Profile
- Antiviral Program - Drug Profile
- MucoCept Platform - Drug Profile
- Zoster Vaccine - Drug Profile
- GEN-003 - Drug Profile
- HSV-2 Px - Drug Profile
- valganciclovir hydrochloride - Drug Profile
- Live Attenuated Human Cytomegalovirus (HCMV) Vaccine - Drug Profile
- CMV specific T Cell donor lymphocyte - Drug Profile
- VCL CT02 pDNA Vaccine + Towne CMV Vaccine - Drug Profile
- PADRE-CMV Fusion Peptide Vaccine + Tetanus-CMV Fusion Peptide Vaccine + Agatolimod Sodium - Drug Profile
- PADRE-CMV Fusion Peptide Vaccine + Tetanus-CMV Fusion Peptide Vaccine - Drug Profile
- HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes - Drug Profile
- RBT-301 - Drug Profile
- valganciclovir hydrochloride - Drug Profile
- PP-9706642 - Drug Profile
- Ganciclovir + Valganciclovir - Drug Profile
- GSK-208136 - Drug Profile
- Chickenpox Vaccine - Drug Profile
- JVRS-100 + HSV-2 Vaccine - Drug Profile
- CMV Vaccine - Drug Profile
- CMV Hyperimmune Globulin - Drug Profile
- CD4 + CD8 T Cells - Drug Profile
- New Thiazolides - Drug Profile
- Drug For Herpes Simplex - Drug Profile
- P-31 - Drug Profile
- Varilrix + Priorix-Tetra - Drug Profile
- MBX-400 - Drug Profile
- vif1 Peptide - Drug Profile
- Valaciclovir + Aciclovir - Drug Profile
- Zoster Vaccine - Drug Profile
- Valaciclovir + Ganciclovir - Drug Profile
- CMV pp65 specific T cells - Drug Profile
- Multi-Virus Cytotoxic T Lymphocytes - Drug Profile
- PGN-632 - Drug Profile
- ID-G103 - Drug Profile
- PN-200 - Drug Profile
- PN-201 - Drug Profile
- Valacyclovir - Drug Profile
- HZ/su vaccine - Drug Profile
- Human Cytomegalovirus Antibodies - Drug Profile
- valganciclovir hydrochloride - Drug Profile
- HSV Program - Drug Profile
- HerpeCide-I - Drug Profile
- acyclovir - Drug Profile
- Monoclonal Antibody For CMV - Drug Profile
- CS-TATI-1 Research Program - Drug Profile
- SB-105 - Drug Profile
- Human Monoclonal Antibodies Program For CMV - Drug Profile
- CMV Vaccine - Drug Profile
- WTCa Adjuvant - Drug Profile
- WTCb adjuvant - Drug Profile
- WTCn adjuvant - Drug Profile
- Herpes Infections Therapeutics – Drug Profile Updates
- Herpes Infections Therapeutics – Discontinued Products
- Herpes Infections Therapeutics - Dormant Products
- Herpes Infections – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Herpes Infections, H2 2012
- Products under Development for Herpes Infections – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Development by Companies, H2 2012 (Contd..2)
- Number of Products under Development by Companies, H2 2012 (Contd..3)
- Number of Products under Development by Companies, H2 2012 (Contd..4)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Development by Companies, H2 2012 (Contd..2)
- Products under Development by Companies, H2 2012 (Contd..3)
- Products under Development by Companies, H2 2012 (Contd..4)
- Products under Development by Companies, H2 2012 (Contd..5)
- Products under Investigation by Universities/Institutes, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..2)
- Vical Incorporated, H2 2012
- GlaxoSmithKline plc, H2 2012
- Antigenics, Inc., H2 2012
- GenVec, Inc., H2 2012
- Merck & Co., Inc., H2 2012
- Piramal Healthcare Limited, H2 2012
- Novartis AG, H2 2012
- Astellas Pharma Inc., H2 2012
- Alfacell Corporation, H2 2012
- CEL-SCI Corporation, H2 2012
- Intercell AG, H2 2012
- Mymetics Corporation, H2 2012
- NanoViricides, Inc., H2 2012
- Nutra Pharma Corporation, H2 2012
- Peregrine Pharmaceuticals, Inc., H2 2012
- CytoGenix, Inc., H2 2012
- Alnylam Pharmaceuticals, Inc, H2 2012
- Flamel Technologies S.A., H2 2012
- Starpharma Holdings Limited, H2 2012
- Summit Corporation plc, H2 2012
- BioAlliance Pharma SA, H2 2012
- Clavis Pharma ASA, H2 2012
- Oryzon, H2 2012
- Functional Genetics, Inc., H2 2012
- Colby Pharmaceutical Company, H2 2012
- Nutri Pharma ASA, H2 2012
- Vironova AB, H2 2012
- Altor BioScience Corporation, H2 2012
- Osel Inc., H2 2012
- AiCuris GmbH & Co. KG, H2 2012
- Cell Medica Limited, H2 2012
- AlphaVax, Inc., H2 2012
- Nitric Biotherapeutics, Inc., H2 2012
- Romark Laboratories, L.C., H2 2012
- Chimerix, Inc., H2 2012
- aRigen Pharmaceuticals, Inc., H2 2012
- Lumavita AG, H2 2012
- Theraclone Sciences, Inc., H2 2012
- Sinovac Biotech Ltd., H2 2012
- Wittycell S.A.S., H2 2012
- Microbiotix, Inc., H2 2012
- NanoBio Corporation, H2 2012
- PharmaNova Inc., H2 2012
- Immune Design Inc., H2 2012
- Redox Pharmaceutical Corporation, H2 2012
- PepTcell Limited, H2 2012
- 4-Antibody AG, H2 2012
- Arisyn Therapeutics Inc., H2 2012
- Epiphany Biosciences, Inc., H2 2012
- Cannabis Science, Inc., H2 2012
- Synergy Pharmaceuticals, Inc., H2 2012
- Genocea Biosciences, Inc., H2 2012
- Variation Biotechnologies, Inc., H2 2012
- AIMM Therapeutics B.V., H2 2012
- China National Pharmaceutical Group Corporation, H2 2012
- Trellis Bioscience, Inc., H2 2012
- Vakzine Projekt Management GmbH, H2 2012
- Spider Biotech S.r.l., H2 2012
- Kala Pharmaceuticals, H2 2012
- Beech Tree Labs, Inc., H2 2012
- FunZyme BioTechnologies S.A., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Herpes Infections Therapeutics – Drug Profile Updates
- Herpes Infections Therapeutics – Discontinued Products
- Herpes Infections Therapeutics – Discontinued Products (Contd..1)
- Herpes Infections Therapeutics – Dormant Products
- Herpes Infections Therapeutics – Dormant Products (Contd..1)
- Herpes Infections Therapeutics – Dormant Products (Contd..2)
- Herpes Infections Therapeutics – Dormant Products (Contd..3)
- Herpes Infections Therapeutics – Dormant Products (Contd..4)
- Herpes Infections Therapeutics – Dormant Products (Contd..5)
- Herpes Infections Therapeutics – Dormant Products (Contd..6)
- Herpes Infections Therapeutics – Dormant Products (Contd..7)
- Herpes Infections Therapeutics – Dormant Products (Contd..8)
- Herpes Infections Therapeutics – Dormant Products (Contd..9)
- List of Figures
- Number of Products under Development for Herpes Infections, H2 2012
- Products under Development for Herpes Infections – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractHerpes Infections – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Herpes Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Herpes Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Herpes Infections. Herpes Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Herpes Infections.
- A review of the Herpes Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Herpes Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Herpes Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Herpes Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
